Yuanxin Huibao Funding, Investors & Competitors

Yuanxin Huibao has raised $243M across 3 funding rounds, most recently a $232M Series F in August 2021.

Last Yuanxin Huibao funding round

$232M

Series F · Aug 2021

Cumulative funding Yuanxin Huibao raised

$243M

across 3 funding rounds

Key investors in Yuanxin Huibao

  • HSG
  • Qiming Venture Partners
  • OrbiMed
  • B Capital
  • Future Ventures
  • CITIC Securities
  • E-Fund
  • Index Capital

Yuanxin Huibao Overview

About Yuanxin Huibao

Yuanxin Huibao is a health insurance technology service provider in China offering coverage for major diseases and chronic conditions. It delivers solutions in product actuarial pricing, risk control, user acquisition, and retention to enhance medical services reliability.


Founded

2019

HQ

ChinaBeijing

Status

Privately held

Customer focus

B2B

Revenue model

Services

Yuanxin Huibao Funding History

Yuanxin Huibao has raised a total of $243M across 3 funding rounds.

Yuanxin Huibao's first fundraising round was a $7M Series A in July 2019. The most recent completed round was a $232M Series F in August 2021.

Yuanxin Huibao funding rounds

Yuanxin Huibao funding rounds
DateStageInvestorsRaisedDeal Summary
Aug 2021Series FHel Ved Capital; Kun Ling Capital; Future Ventures; Index Capital; ACE Capital; E-Fund; OrbiMed; B Capital; Bank of China Investment Management; ABI Yuanshi capital; CITIC Securities; HSG$232MYuanxin Huibao is a Beijing-based medical insurance company, incubated by Yuanxin Technology (Yuanxin Keji), specializing in health insurance products like specialized drug insurance for cancer treatments and supplementary medical insurance. Founded in July 2019, it leverages big data from its parent company's ecosystem, including Miaoshou Doctor with 20 million registered users and 30,000 doctors, to design targeted insurance solutions for patients, hospitals, pharmaceutical companies, and insurers. In August 2021, Yuanxin Huibao's parent Yuanxin Technology announced completion of a Series F financing round exceeding RMB 1.5 billion (approximately $231.6 million), with investors including ABI Capital (likely ABI Yuanshi), B Capital Group, Hel Ved Capital, OrbiMed, E Fund, Bank of China International (related to Bank of China Investment Management), CITIC Securities, Index Capital, Kunhui Capital (likely Kun Ling), Future Innovation (likely Future Ventures), and others matching the query's list. Index Capital served as exclusive financial advisor. This aligns closely with the approximate March 8, 2021 date, though announced later. The company rapidly grew post-launch, achieving over 50% market share in China's cancer drug insurance segment within months, partnering with platforms like WeChat and Ant Financial, and launching products like 'Yao Anxin' (first specialized drug insurance, exceeding 3 million policies in 3 days) and 'Shanxi inclusive medical insurance.' Earlier Series A funding in 2019 was CNY 50 million from Sequoia Capital China and Qiming Venture Partners.
Dec 2019Series AQiming Venture Partners (lead)$4MYuanxin Huibao is a health insurance technology company incubated by parent Yuanxin Keji and founded in July 2019, focusing on medical insurance products for cancer treatment using big data from sister company Miaoshou Doctor's ecosystem of 20 million registered users, 3 million DAUs, 30,000 doctors, and hundreds of pharmacies. The company secured a Series A funding round from Sequoia Capital and Qiming Venture Partners worth CNY 50 million, equivalent to approximately $7.25 million, and quickly advanced to Series A+. It leverages parent company support for data, technology, oncologist and pharmacy networks, and insurance licenses to serve cash-rich insurance companies, claiming the largest market share in China's cancer-related insurance field despite being a late entrant. Qiming Venture Partners had a prior relationship with the CEO from consulting work in online insurance. Later funding includes a Series F at CN¥1.6B valuation, but details for the 2019 Qiming-led round lack valuation or financial metrics.
Jul 2019Series AHSG (lead); Qiming Venture Partners$7M-

Who has invested in Yuanxin Huibao?

13 investors have backed Yuanxin Huibao across its funding rounds, including HSG, Qiming Venture Partners, OrbiMed, B Capital, Future Ventures and CITIC Securities.

Lead investors include Qiming Venture Partners and HSG.


Yuanxin Huibao Investors

Investors in Yuanxin Huibao by funding rounds participated
InvestorHQRoundsRoleFirst check
Qiming Venture PartnersChinaShanghai2LeadJul 2019
HSGHong KongHong Kong2LeadJul 2019
Hel Ved CapitalHong KongHong Kong1ParticipantAug 2021
Kun Ling CapitalChinaShanghai1ParticipantAug 2021
Future VenturesUnited StatesSan Francisco, CA1ParticipantAug 2021
Index CapitalChinaBeijing1ParticipantAug 2021
ACE CapitalTaiwanTaichung1ParticipantAug 2021
E-FundCanadaVancouver1ParticipantAug 2021
OrbiMedUnited StatesNew York City, NY1ParticipantAug 2021
B CapitalUnited StatesLos Angeles, CA1ParticipantAug 2021
Bank of China Investment ManagementChinaShanghai1ParticipantAug 2021

This data is available for Pro users. Sign up to see all 13 Yuanxin Huibao investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Yuanxin Huibao Competitors

Yuanxin Huibao competitors include listed companies like Elevance Health and Cigna Group, and private ones like wefox, Root Insurance, Marshmallow and Ominimo.

Public and private companies comparable to Yuanxin Huibao
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
wefoxGermanyBerlinPrivate$850M-$4.6B5.4x
Root InsuranceUnited StatesColumbus, OHPrivate$43M$132M$3.6B-
MarshmallowUnited KingdomUnited KingdomPrivate$500M-$2B4.0x
OminimoHungaryHungaryPrivate$350M-$1.6B4.6x
Elevance HealthUnited StatesUnited StatesPublicly listed$199B$9.7B$90B0.6x
Cigna GroupUnited StatesUnited StatesPublicly listed$274B$12B$73B0.3x

Yuanxin Huibao Public Comps

Yuanxin Huibao is still privately-owned, but its public comps include Berkshire Hathaway, UnitedHealth Group, Allianz, China Life, Ping An Insurance, Chubb, Progressive, Zurich Insurance Group, AXA and AIA Group.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Berkshire Hathaway$411B$101B2.9x3.0x11.7x-
UnitedHealth Group$448B$23B0.9x0.9x16.7x13.3x
Allianz$158B$20B1.3x0.9x10.2x10.0x
China Life$90B$28B1.8x1.7x5.8x6.0x
Ping An Insurance$138B$13B7.3x6.3x77.0x-
Chubb$60B$14B2.7x2.7x11.2x11.8x
Progressive$88B$15B1.5x1.5x9.0x8.8x
Zurich Insurance Group$89B$11B1.4x1.8x10.6x16.0x

This data is available for Pro users. Sign up to see all Yuanxin Huibao competitors and their valuation data.

Start Free Trial

Common questions about Yuanxin Huibao

When was Yuanxin Huibao founded?Yuanxin Huibao was founded in 2019.
Where is Yuanxin Huibao headquartered?Yuanxin Huibao is headquartered in Beijing, China.
Is Yuanxin Huibao publicly listed?No, Yuanxin Huibao is a private, VC-backed company.
How much funding has Yuanxin Huibao raised?Yuanxin Huibao has raised $243M across 3 funding rounds.
What was Yuanxin Huibao's last funding round?Yuanxin Huibao's last funding round was a $232M Series F in August 2021.
Who are Yuanxin Huibao's investors?Yuanxin Huibao's investors include Qiming Venture Partners, HSG, Hel Ved Capital, Kun Ling Capital, Future Ventures, Index Capital, ACE Capital, E-Fund, OrbiMed, B Capital and 3 others.
Which companies are comparable to Yuanxin Huibao?Companies comparable to Yuanxin Huibao include wefox, Root Insurance, Marshmallow, Ominimo, Elevance Health and Cigna Group.

See companies similar to Yuanxin Huibao

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial